Close Menu

NEW YORK – Healthcare artificial intelligence firm Tempus announced earlier this week the acquisition of Akesogen, the owner of a commercial laboratory and provider of genomics and clinical trial precision medicine services.

Tempus said that the acquisition strengthens its expansion into disease areas outside of cancer and provides it with strategic capabilities in addition to those provided by its Chicago laboratory.

Financial and other terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.

In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.